12. The evaluation of clinical, histological and molecular predictive and grognostic factors in patients with advanced squamous cell cancer of the larynx, meso- and hypopharynx, floor of mouth irradiated after induction chemotherapy  by Małecki, K.
Conclusions: Mean doses in tumour varied
from 102.9 Gy to 268.2 Gy depending on the
tumour size. Doses in selera and lens did not
exceed the tolerance levels in all three groups ot
patients.
12.
THE EVALUATION OF CLINICAL,
HISTOLOGICAL AND MOLECULAR
PREDICTIVE AND GROGNOSTIC
FACTORS IN PATIENTS WITH
ADVANCED SaUAMOUS CELL
CANCER OF THE LARYNX, MESO-
AND HYPOPHARYNX, FLOOR OF
MOUTH IRRADIATED AFTER
INDUCTION CHEMOTHERAPY
K. Małecki
Centrum Onkologii, Klinika Radioterapii Kraków,
Polska
Setween 1988-1997198 patients with HNSCC
received induction chemotherapy. Clinical
staging was as follows 11-7(52%), 111-45(20%),
IV-146(64%). Patients received 1 to 4 cycles of
Cisplatin + 5FU. Response to chemotherapy
(CR or PRl was observed only in patients who
received 2-4 cycles ot chemotherapy. The best
responses were observed in patients with
laryngeal, mesopharyngeal and hypopharyngeal
cancers, 55%. Radiotherapy was subsequently
performed in 178(90%). Twenty patients were
not irradiated because of poor performance
status or progression ot disease after
chemotherapy. Radical radiotherapy was
performed in 124 (5-year LC 38%, DFS 35%,
DSS 43%, OS 30%). Ali 25 patients irradiated
palliatively dyied during 26 months. The best
results were observed in patients with laryngeal
cancer; LC 48%, DFS 25%, DSS 32%, OS 22%.
The most trequent failure was local recurrence
in 29(23%) patients. In the next step of this
study we want; 1) to assess prognostic and
predictive value ot selected clinical, histological
and molecular factors by detining its influence
on the chance ot response to chemotherapy and
chance of cure 2) to examine the correlation
between theses factors and to establish if they
give new predictive and prognostic intormation
3) to establish which ot examined factors may
be usetul in selecting patients with advanced
HNSCCs to combined modality treatment
(chemotherapy + radiotherapy), and particularily
32
in selecting patients with advanced laryngeal
cancer to larynx preservation treatmenł. We will
examine the celi cycle parameter Ki67,
expression ot p53 protein and expresion ot
(EGFr). There will be also reevaluated
histological material (grading).
13.
IMMUNOGENETHERAPY COMBINED
WITH BRAIN METASTASES
IRRADIATION IN MELANOMA
PATIENTS
S. Nawrocki, A. Karczewska, P. Mileckl,
O. lżycki, G. Stryczyńska, A. Mackiewicz
Greatpoland Cancer Centre, USaMS, Poznań,
Poland
Aims: To assess toxicity and results ot
melanoma brain metastases irradiation in
patients treated with genetically moditied tumour
vaccine.
Materials/methods: A group of 45 melanoma
stage IV (AJCC) patients was treated with
vaccine consisted of autologic melanoma cells
admixed with allogeneic cells modified with IL-6
and sIL-BR genes. During the treatment 14
patients developed symptoms ot brain
metastases. 5 patients had solitary metastases,
9 multiple lesions. 4 patients with single
metastasis were treated surgically. Ali 14
patients were irradiated with the doses 30-39
Gy, using 3 Gy/tracion, 5 fractions/week.
Toxicity of cranial irradiation (c1inically, eT) and
clinical results (CT, survival) were evaluated.
Immunological cellular responses were
assessed in vitro.
Results: Acute effects ot irradiation were
tolerable and manageable using standard
dexamethasone treatment. There was no
radiation encephalopathy or radiation necrosis.
In 7/14 patients stabilization er partial remission
of brain lesions was observed. Overall survival
measured trom brain metastases diagnosis
ranged from 2 to 21 months (2 patients are stil!
alive), median survival was 316 days. In 4
treated patients radiation enhanced immune
responses to the vaccine.
Conclusions: Palliative cranial irradiation is
well tolerated by patients treated with novel
systemie approaches such as immunogene
therapy, relives symptoms and may extend
survival. Radiation ot metastases modulates
immune responses to melanoma cells.
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